Abstract
BackgroundDespite a demonstrated superiority of interleukin-6 over tumour necrosis factor (TNF) blockade when used as monotherapy, the choice of the first biologic agent (bDMARD) for treating rheumatoid arthritis (RA) in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have